Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents for HIPEC have not been established. Melphalan is a drug with broad activity and a favorable profile for intraperitoneal application. The purpose of...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/827534 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560345854509056 |
|---|---|
| author | Lana Bijelic Paul H. Sugarbaker O. Anthony Stuart |
| author_facet | Lana Bijelic Paul H. Sugarbaker O. Anthony Stuart |
| author_sort | Lana Bijelic |
| collection | DOAJ |
| description | Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents for HIPEC have not been established. Melphalan is a drug with broad activity and a favorable profile for intraperitoneal application. The purpose of this study is to review our experience using melphalan for HIPEC. Pharmacologic data was obtained. Thirty four patients who underwent CRS for peritoneal metastases received melphalan for HIPEC between 2003 and 2011. The first 10 patients received 70 mg/m2; subsequent 24 received 60 or 70 mg/m2. The mean PCI was 21±7. Twenty-eight patients (83%) had a CC score of 1 or 2. The mean length of stay was 18±2 days. Nine patients (26%) had a grade 3 and 6 (17%) had grade 4 morbidity. There were no postoperative deaths. The pharmacologic analysis of plasma to peritoneal fluid levels of melphalan showed an AUC ratio of 33 while the tumor nodules to peritoneal ratio was 8. Melphalan is an acceptable agent for use in HIPEC. The morbidity of intraperitoneal melphalan at the dose of 60–70 mg/m2 appears acceptable. Further studies comparing the effectiveness of melphalan and other HIPEC agents are needed. |
| format | Article |
| id | doaj-art-c4556d2551bb432d8b9cbd3c3639b546 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-c4556d2551bb432d8b9cbd3c3639b5462025-02-03T01:27:51ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/827534827534Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 PatientsLana Bijelic0Paul H. Sugarbaker1O. Anthony Stuart2Washington Cancer Institute, Washington, DC 20010, USAWashington Cancer Institute, Washington, DC 20010, USAMedStar Health Research Institute, Washington, DC 20010, USACytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents for HIPEC have not been established. Melphalan is a drug with broad activity and a favorable profile for intraperitoneal application. The purpose of this study is to review our experience using melphalan for HIPEC. Pharmacologic data was obtained. Thirty four patients who underwent CRS for peritoneal metastases received melphalan for HIPEC between 2003 and 2011. The first 10 patients received 70 mg/m2; subsequent 24 received 60 or 70 mg/m2. The mean PCI was 21±7. Twenty-eight patients (83%) had a CC score of 1 or 2. The mean length of stay was 18±2 days. Nine patients (26%) had a grade 3 and 6 (17%) had grade 4 morbidity. There were no postoperative deaths. The pharmacologic analysis of plasma to peritoneal fluid levels of melphalan showed an AUC ratio of 33 while the tumor nodules to peritoneal ratio was 8. Melphalan is an acceptable agent for use in HIPEC. The morbidity of intraperitoneal melphalan at the dose of 60–70 mg/m2 appears acceptable. Further studies comparing the effectiveness of melphalan and other HIPEC agents are needed.http://dx.doi.org/10.1155/2012/827534 |
| spellingShingle | Lana Bijelic Paul H. Sugarbaker O. Anthony Stuart Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients Gastroenterology Research and Practice |
| title | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
| title_full | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
| title_fullStr | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
| title_full_unstemmed | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
| title_short | Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients |
| title_sort | hyperthermic intraperitoneal chemotherapy with melphalan a summary of clinical and pharmacological data in 34 patients |
| url | http://dx.doi.org/10.1155/2012/827534 |
| work_keys_str_mv | AT lanabijelic hyperthermicintraperitonealchemotherapywithmelphalanasummaryofclinicalandpharmacologicaldatain34patients AT paulhsugarbaker hyperthermicintraperitonealchemotherapywithmelphalanasummaryofclinicalandpharmacologicaldatain34patients AT oanthonystuart hyperthermicintraperitonealchemotherapywithmelphalanasummaryofclinicalandpharmacologicaldatain34patients |